EXAS - NASDAQ

Exact Sciences Corporation

Exact Sciences Corporation

EXAS·NASDAQ

$104.91

+0.0000%
HealthcareMedical - Diagnostics & Research

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$20.03B
EPS-1.1000
P/E Ratio-95.37
Earnings Date04/29/2026
491.44M
Operating Cash Flow
133%
3Y-320.0%
5Y+260.0%
10Y-478.0%
195.12M
Investing Cash Flow
-144%
3Y+163.0%
5Y-128.0%
10Y-1794.0%
-338.09M
Financing Cash Flow
-246%
3Y-542.0%
5Y-118.0%
10Y-326.0%
EXAS

Exact Sciences Corporation Cash Conversion Engine

EXAS · NASDAQ
Net Income-207.95M
Depreciation & Amortization221.58M
Stock-Based Compensation217.67M
Change in Working Capital121.83M
Others139.86M
Capital Expenditures-134.66M
Free Cash Flow356.78M

Cash Flow Quality Analysis

FCF Conversion Rate

-171.6%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

27.4%

Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.

FCF Growth Trend

+378.6%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$121.83M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Exact Sciences Corporation Cash Flow Statement

EXAS • NASDAQ

Exact Sciences Corporation Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
OPERATING ACTIVITIES
Net Income
-207.9M
-1B
-204.1M
-623.5M
-595.6M
-848.5M
-213.1M
-175.1M
-114.4M
-167.2M
-157.8M
-100M
-46.5M
-52.4M
-28.7M
-11.6M
-9.1M
-9.7M
-12M
-12.9M
Depreciation & Amortization
221.6M
214.9M
206.6M
197.6M
180.3M
163.4M
50.2M
23.1M
15.6M
11.5M
7.8M
3.7M
1.4M
985K
411K
230K
175K
626K
-2.2M
-3M
Change in Deferred Taxes
-1.5M
-10.1M
-955K
-11.9M
-253.2M
-9.9M
-193.6M
-2.8M
-115K
800K
363K
891K
736K
532K
24.5M
-5.3M
0.0
-1.4M
-2.7M
-3M
Stock-Based Compensation
217.7M
214.9M
231.3M
206.8M
253.1M
152.9M
108.5M
60.3M
35.5M
23.7M
18.1M
11.5M
7.7M
5.5M
4.3M
2.2M
2.6M
1M
2.8M
3M
Other Non-Cash Items
139.9M
875.8M
-76.4M
33.8M
202M
721.3M
189.9M
26.2M
-601K
-347K
-529K
-294K
-4.1M
-3M
-28.6M
107K
1.8M
66K
2.8M
3M
Change in Working Capital
121.8M
-56M
-342K
-26.4M
111.1M
-42.7M
-53.6M
-911K
-7.7M
1.5M
-1.8M
3.3M
1.5M
4.2M
221K
810K
-8.1M
1.5M
2.5M
763K
Cash from Operating Activities
491.4M
210.5M
156.1M
-223.6M
-102.2M
136.5M
-111.7M
-69.3M
-71.7M
-130.1M
-134M
-80.9M
-39.3M
-44.2M
-27.8M
-13.5M
-12.6M
-7.9M
-8.8M
-12.2M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
-134.7M
-136M
-124.2M
-214.5M
-135.8M
-64.4M
-172.7M
-150.7M
-69.2M
-14.9M
-22M
-12.5M
-9.3M
-681K
-2.1M
-626K
-462K
-104K
-132K
-394K
Acquisitions, Net
-75M
-45M
-52.4M
-14.7M
-517.8M
-22.6M
-973.9M
-17.9M
-6M
(230K)
(1.9M)
-240K
(47K)
(92K)
-15K
-2K
-1K
(100K)
(0.0)
(245K)
Purchase of Investments
-195.8M
-466.8M
-156.4M
-174.3M
-1.2B
-1.1B
-634.1M
-1.2B
-357.1M
-190M
-205.1M
-209.5M
-98.5M
-96M
-87M
-24.5M
-18.9M
-3.5M
-20.7M
-31.4M
Sale/Maturity of Investments
572.3M
205.8M
383M
453.1M
794.3M
886.7M
1.7B
579.2M
271.5M
193.3M
162.3M
104.2M
72.3M
58.4M
46.1M
10.2M
16.5M
11.5M
28.8M
36.3M
Other Investing Items
28.3M
-225K
-250K
24.5M
-58.8M
-411.8M
-1M
-614.3M
-109.3M
-230K
-1.9M
240K
-47K
-92K
15K
2K
1K
174K
8K
-245K
Cash from Investing Activities
(195.1M)
-442.2M
(49.7M)
(74.1M)
-1.1B
-702M
-124.4M
-781.9M
-160.8M
-11.5M
-64.8M
-117.8M
-35.5M
-38.3M
-43M
-14.9M
-2.9M
(8.2M)
(8M)
(4.5M)
FINANCING ACTIVITIES
Net Issuance of Common Stock
28.4M
32.9M
0.0
0.0
0.0
861.7M
0.0
0.0
253.4M
144.2M
174.1M
238.6M
73.3M
57.8M
27.2M
82.3M
14.1M
0.0
286K
253K
Net Issuance of Debt
-249.2M
216.8M
138M
50M
-23.7M
974.2M
236.1M
920.7M
-376K
-166K
4.7M
2M
-333K
-107K
0.0
0.0
1M
0.0
0.0
0.0
Share Repurchases
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(4.9M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Other Financing Items
-117.4M
-17.8M
21.8M
26.5M
32.2M
43.7M
17.1M
13.5M
7.9M
5.5M
3M
242M
1.8M
2.4M
685K
2.9M
17.4M
107K
100K
220K
Cash from Financing Activities
-338.1M
231.9M
159.8M
76.5M
8.5M
1.9B
253.2M
934.1M
261M
149.6M
181.8M
244M
74.8M
60M
27.9M
85.2M
32.5M
107K
386K
473K
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates
891K
-3.3M
1.3M
30K
23K
0.0
0.0
36K
143K
-215K
11K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net Change in Cash
349.4M
-3M
366.9M
-73M
-1.2B
1.3B
17.1M
82.9M
28.6M
7.8M
-17M
45.3M
-494K
-22.4M
-43M
56.8M
17M
451K
-345K
-7.2M
Cash at Beginning of Period
606.6M
609.7M
242.8M
315.8M
1.5B
177.5M
160.4M
77.5M
48.9M
41.1M
58.1M
12.9M
13.3M
35.8M
78.8M
21.9M
4.9M
4.5M
4.8M
12M
Cash at End of Period
956M
606.6M
609.7M
242.8M
315.8M
1.5B
177.5M
160.4M
77.5M
48.9M
41.1M
58.1M
12.9M
13.3M
35.8M
78.8M
21.9M
4.9M
4.5M
4.8M
Free Cash Flow
356.8M
74.5M
31.9M
-438M
-238M
72.1M
-284.3M
-220M
-141M
-144.9M
-156M
-93.4M
-48.6M
-44.8M
-29.9M
-14.1M
-13.1M
-8M
-8.9M
-12.5M

SEC Filings

EXAS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

March 23, 2026
March 23, 2026
2026
View Filing
8-K

8-K 2026

N/A

March 20, 2026
March 19, 2026
2026
View Filing
8-K

8-K 2026

N/A

February 20, 2026
February 20, 2026
2026
View Filing
10-K

10-K 2025 FY

FY

February 13, 2026
December 31, 2025
2025
View Filing
8-K

8-K 2026

N/A

February 13, 2026
February 13, 2026
2026
View Filing
8-K

8-K 2026

N/A

February 10, 2026
February 10, 2026
2026
View Filing
8-K

8-K 2025

N/A

December 29, 2025
December 23, 2025
2025
View Filing
8-K

8-K 2025

N/A

November 20, 2025
November 19, 2025
2025
View Filing
10-Q

10-Q 2025 Q3

Q3

November 03, 2025
September 30, 2025
2025
View Filing
8-K

8-K 2025

N/A

November 03, 2025
November 03, 2025
2025
View Filing
Showing 1 to 10 of 471 filings

Related Guides

Blog Categories

Continue your EXAS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.